All posts by imreal

Impact of Antimicrobial Stewardship Intervention in Conjunction with Rapid Multiplex Respiratory Diagnostics, Upcoming Webinar Hosted by Xtalks


Rapid identification of viral etiologies and differentiating them from bacterial can improve patient management and lead to optimized antibacterial and antiviral use, assist with decisions on hospital admission and infection control and improve clinical and economic outcomes.

Respiratory tract infections (RTIs) are the leading cause of death from infectious disease and the most common reason for empiric antimicrobial use in the US. Viruses are the causative pathogen in half to two-thirds of patients hospitalized with an RTI. Therefore, rapid identification of viral etiologies and differentiating them from bacterial can improve patient management and lead to optimized antibacterial and antiviral use, assist with decisions on hospital admission and infection control and improve clinical and economic outcomes.

The advent and widespread adoption of antimicrobial stewardship (AMS) has improved the overall quality of care for patients afflicted with infectious syndromes and has helped to preserve antibiotics for future patients. Among the many tried-and-true AMS intervention strategies, the use of rapid diagnostic tests (RDTs) has quickly established itself as one of the most impactful. While robust data exist supporting RDTs for bloodstream infections, considerably less guidance is available for RTI RDTs, especially lower RTIs (LRTIs). Despite this, the potential impact of RTI RDTs on patient outcomes and AMS metrics is substantial given the uncertainty that plagues diagnosis and treatment of RTIs.

The complexity of RTIs and available multiplex RDTs necessitates close collaboration between clinicians and laboratorians to ensure proper implementation, interpretation and communication of test results.

In this webinar, the featured speaker will explain how RTI RDTs can enable quick and definitive pathogen identification to support antimicrobial stewardship efforts and optimize clinical and economic outcomes. Additionally, the speaker will provide guidance and examples of how to evaluate and compare RDTs using institutional data, follow optimal diagnostic stewardship principles and assess the impact of these assays.

Join Eric Wenzler, PharmD, BCPS, BCIDP, AAHIVP, Department of Pharmacy Practice, University of Illinois, Chicago College of Pharmacy, USA, for the live webinar on Monday, September 12, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Impact of Antimicrobial Stewardship Intervention in Conjunction with Rapid Multiplex Respiratory Diagnostics.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

A single injection hepatitis B cure drug attracts international attention


News Image

“Imagine a single-dose treatment that can save a child from a lifetime of health challenges. Dr. Zhang is truly passionate about affecting this change.” – Kathie Callahan Brady, CEO, Frederick Innovative Technology Center, Inc.

HBVtech, a biopharma startup company within the Frederick Innovation Technology Center (FITCI), is garnering international attention for its work creating a single-dose injection-based hepatitis B cure. Founder and Chief Science Officer, Dr. Yong-Yuan Zhang is well known for his research and writing on the topic of hepatitis, including related functional genomics and rapid production of neutralizing antibodies studies. (1)

Dr. Zhang started HBVtech in 2013 and is developing a hepatitis B drug, HBVZ10, that is poised to change the lives of 240 million people across the planet. Once established, the disease is often transmitted from mother to child, creating a generational cycle of transmission, especially in underserved populations. While the hepatitis B virus (HBV) frequently causes transient infections in adults, it often results in chronic infection in infants. The Centers for Disease Control and Infections (CDC) notes that, “as many as 90% of infants born to HBV-infected mothers in the United States will become infected with HBV. Subsequently, 90% of those infants develop chronic HBV infection and approximately one-fourth of these infants eventually will die from liver-related complications.” (2)

HBVtech established proof of three concepts, demonstrating superior efficacy over known drugs in curing hepatitis B virus (HBV) infection. The work uses an HBV infected uPA/SCID chimeric mice model because it faithfully correlates to HBV infection features in humans. (3)

In March this year, HBVtech presented details about their new HBV cure at the plenary session at the 2022 Asia Pacific Association of the Study of Liver (APASL) meeting in Seoul, South Korea. In September, HBVtech will present a poster at the 2022 HBV International Meeting in Paris, France. Another presentation follows in November at DC’s Walter E. Washington Convention Center for the 2022 American Association of the Study of Liver Diseases Meeting, the biggest and most prestigious international liver conference. (4)

Dr. Zhang is dedicated to raising awareness about the disease, its impact, and prevention.

Ally Kathie Callahan Brady is CEO of FITCI, a life science business incubator/accelerator and HBVtech’s home base. She says, “This is such an exciting project. Imagine a single-dose treatment that can save a child from a lifetime of health challenges. Dr. Zhang is truly passionate about affecting this change. It’s a calling to contribute something that makes the world a better place and that is the heart of innovation.” (5)

(1) http://www.researchgate.net/profile/Yong-Yuan-Zhang

(2) https://www.cdc.gov/nchhstp/pregnancy/effects/hbv.html

(3) Zhang, Yong-Yuan. (2017). New Strategy Treating Hepatitis B Virus (HBV) Infection: A Review of HBV Infection Biology. 10.5772/66083.

(4) Oral presentation no: 95 in 2021 AASLD meeting and appears in Hepatology VOLUME 74, NUMBER 1 (SUPPL) page 65A; Poster presentation THU303 in 2022 EASL meeting and appears in Journal of Hepatology 2022 vol. 77(S1) page S245.

Share article on social media or email:

Cipher Skin Partners with Kno2 to Unlock Data Sharing with the Entire Healthcare Ecosystem


News Image

With Kno2, Cipher Skin can effectively communicate data collected to other healthcare platforms; bridging the gaps between referring physicians, patients, and physical therapists, while enabling more effective treatment and patient-centered care.

Cipher Skin, the hardware-enabled monitoring platform that enables flexible, hybrid recovery for musculoskeletal care and Kno2®, the company leading the future of healthcare communication, today announced plans to incorporate Kno2’s connectivity platform into the Cipher Skin technology to set communication free between physician referrers, physical therapists and the technology they use, enabling greater care coordination and data sharing.

Cipher Mesh, Cipher Skin’s patented technology, wraps around upper and lower extremities, captures gapless biometric and motion data, and translates it into instant, actionable insights. Physical and occupational therapists, athletic trainers, and orthopedists can evaluate patient conditions, build their treatment plans, and monitor progress over time.

When Cipher Skins becomes Kno2 Connected™, this data can be easily shared with every Certified Electronic Health Record Technology ([CEHRT) system, keeping healthcare providers informed about their patient’s health and progress.

“We’re thrilled to work with a strong partner like Kno2 to help connect Cipher Skin’s Recovery App to the rest of the healthcare ecosystem,” said Philip Bogdanovich, founder and CEO at Cipher Skin. “This exciting partnership reinforces our commitment to deliver end-to-end visibility of the recovery journey through improved patient monitoring and outcomes tracking. With Kno2, Cipher Skin can effectively communicate data collected to other healthcare platforms; bridging the gaps between referring physicians, patients, and physical therapists, while enabling more effective treatment and patient-centered care.”

“What good is data collected if it cannot be communicated in a timely manner to inform care decisions,” said Jon Elwell, CEO at Kno2. “The Cipher Skin technology is impressive with its ability to track real-time movement and biometrics of the human body in motion – the type of innovation that is getting jaw-dropping reaction from the healthcare industry.” Elwell continues, “We are excited they selected us as their communication provider. Kno2 is connected to all the major EHRs in the post-acute and therapy care settings, and we look forward to introducing Cipher Skin to Kno2’s network.”

To learn more about the first MSK monitoring platform to enable flexible, hybrid recovery through the Biosleeve®, – visit cipherskin.com.

About Cipher Skin

Cipher Skin is a hardware-enabled monitoring platform that enables flexible, hybrid recovery for musculoskeletal care. Founded in 2017, Cipher Skin’s patented technology is a network of sensors that captures gapless biometric and motion data and translates it through proprietary software to provide instantaneous, visualized data and diagnostics. By connecting in-clinic rehab therapy with at-home care through continuous patient progress monitoring, practitioners can track exact outcomes, deliver patient-centered care, and maximize clinic revenue. To learn more visit cipherskin.com.

About Kno2

The Kno2 network enables the secure, effortless, and maximized exchange of patient information across patients, providers, payers and IT vendors. We are empowering healthcare to finally realize the true potential of interoperability by unleashing connectivity everywhere through a simple to use Communication API and robust tools for any business. With industry disrupting economics and our passion to include the underserved, Kno2 is democratizing healthcare communications and defining the new connected future of healthcare. With a single connection to Kno2, anyone can quickly gain access to a powerful network of connected networks, EHRs, HIEs, organizations, technologies and interoperability frameworks that gives the freedom to easily communicate with all. To learn more, visit http://www.kno2.com.

Share article on social media or email:

Meridian Partners with Pioneer Heart Institute to Conduct Cardiovascular Clinical Trials in Lincoln


Meridian Partners with Pioneer Heart Institute to Conduct Cardiovascular Clinical Trials in Lincoln

Meridian Partners with Pioneer Heart Institute to Conduct Cardiovascular Clinical Trials in Lincoln

“Clinical trials can be particularly valuable for people experiencing rare or severe cardiac diseases that don’t have therapeutic options on the market. These trials can help us develop better ways to identify, evaluate, and treat heart conditions.” – Steve Martin, MD. FACC, Pioneer Heart Institute

Meridian Clinical Research, a leading multi-specialty investigative research site network, has partnered with Pioneer Heart Institute, a premier provider of comprehensive cardiac and vascular care in Lincoln, NE. The research site will be located within the Lincoln Pioneer Heart Institute clinic at 6940 Van Dorn St, Ste 201, Lincoln, NE, 68506.

The following cardiologists at Pioneer Heart will serve as principal investigators at Meridian:

As principal investigators, the physicians will oversee clinical trials for drugs, medical devices, and diagnostics intended to help assess and treat cardiovascular disorders, such as heart disease, hypertension, stroke, hyperlipidemia, and other heart, vascular, and blood conditions.

Nicole Osborn, Founder and CEO of Meridian, said the company looks forward to opening its eleventh site in Nebraska. “We’ve made a commitment to bring more therapeutically specialized trials — like cardiovascular studies — to patients seeking care for heart and blood disorders,” said Osborn. “Pioneer Heart’s cardiologists are well-known in our region, and they have the expertise and technology to provide excellent support for Sponsors and CROs developing cardiovascular health products.”

“We’re looking forward to bringing more research and care opportunities to Lincoln,” said Dr. Martin “Clinical trials can be particularly valuable for people experiencing rare or severe cardiac diseases that don’t have therapeutic options on the market. These trials can help us develop better ways to identify, evaluate, and treat heart conditions.”

Meridian now has 36 sites nationwide. Since opening in Omaha in 1999, Meridian has enrolled more than 85,000 patients in 3,400 clinical trials.

If you’re interested in joining a clinical trial at Meridian or want to sign up to learn about upcoming studies, visit mcrmed.com/find-study. For more information about careers at Meridian and current openings in Lincoln, visit mcrmed.com/careers.

***

ABOUT MERIDIAN CLINICAL RESEARCH

Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is a multi-specialty site network headquartered at its dedicated research center in Omaha, NE, and conducts Phase 1-4 clinical trials at investigative sites nationwide. Meridian supports research across numerous therapeutic areas and excels in high-volume vaccine trials. For more information, visit mcrmed.com.

MEDIA INQUIRIES

Robert Jones

Meridian Clinical Research

rjones@mcrmed.com

Share article on social media or email:

Disrupting Data Science in Neuroscience Research and AI


Dimitri Yatsenko

What neuroscience teams want to achieve logically and computationally requires infrastructure, communication, and organization across departments. Commercial companies can provide computation as a service rather than having each lab reproduce the same computation with graduate students.

In 2013, then-President Obama launched the brain initiative, which allocated funding to map every neuron in the brain. Understanding how the brain works can revolutionize the lives of many Americans, solving the complex problems of Alzheimer’s and Parkinson’s disease, depression, and traumatic brain injury (1). However, mapping the brain alone does not reveal how it functions. Different parts of the brain appear similar but function differently, and each person has unique brain anatomy (2).

Neuroscientists have historically worked alone on individual projects, but as technology and data advance, they have to team up to achieve meaningful results. The need for data analysis has allocated neuroscience graduate students to solving complex computer science problems. This presents two significant problems. First, the number of years to achieve a neuroscience Ph.D. is increasing. Second, each graduate student solves the problems presented to them in isolation, which fails to create continuity either after they leave or between research teams. The result is a vast amount of available data failing to achieve its potential. Enter “stabilizing” disruptor Dimitri Yatsenko, CEO of DataJoint, who explains to Karla Jo Helms, host of the Disruption Interruption podcast, that to be used effectively for the greater good, the vast data recorded about the brain has to be analyzed with continuity between universities, laboratories, and research teams.

Dimitri Yatsenko’s background in computer science gave him a unique perspective when his fascination with the human brain led him to neuroscience. He saw independent labs repeatedly reinventing ways of doing data analysis, weighing grad students down with data analysis that had little to do with their passions, and falling short of their collaborative potential. Dimitri said to himself, THAT’S IT — I’M DONE WITH THE STATUS QUO and began to develop a computational framework to create continuity across projects, teams, and applications. He made it cloud compatible, containerized, and web-accessible so it can be quickly deployed for multi-lab collaborations, and DataJoint was born.

Dimitri explains:

We have more data gathered about the brain and its circuits than at any other time in history. We need to combine molecular, genetic, and electrophysiology data, which is beyond the scope of any single neuroscientist. Understanding the brain requires a systematic approach to data and modeling.

Progress is limited by the tsunami of data and the systems required to model and analyze it.

Up to half of the time spent on any neuroscience project is software engineering and systems engineering.

Neuroscientists are fundamentally curious about how the brain, its circuits, our interaction with the environment, and our genetic programming work to produce intelligence. However, the next level of understanding relates to how molecules, genes, and stimuli interact to shape circuits and how circuit systems produce adaptive behavior.

The brain is complex but has patterns to it. You can make the same circuits of the neocortex (the outer portion of the mammalian brain) solve very different problems. The more we understand the principles of how this works, the more effectively we can apply machine learning to understand how circuits and populations of neurons work together in the living brain.

What neuroscience teams want to achieve logically and computationally requires infrastructure, communication, and organization across departments. They haven’t had the tools to support this requirement, and it’s adding to the overhead costs of research.

Commercial companies can help execute things more effectively and provide computation as a service rather than having each lab reproduce the same computation with graduate students.

DataJoint provides a systematic framework to work with data and computation and bridge communication gaps in one unified framework.

Disruption Interruption is the podcast where you’ll hear from today’s biggest Industry Disruptors. Learn what motivated them to bring about change and how they overcome opposition to adoption.

Disruption Interruption can be listened to via the Podbean app, and is available on Apple’s App Store and Google Play.

About Disruption Interruption:

Disruption is happening on an unprecedented scale, impacting all manner of industries — MedTech, Finance, IT, eCommerce, shipping and logistics, and more — and COVID has moved their timelines up a full decade or more. But WHO are these disruptors, and when did they say, “THAT’S IT! I’VE HAD IT!”? Time to Disrupt and Interrupt with host Karla Jo “KJ” Helms, veteran communications disruptor. KJ interviews bad a**es who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits — and not-so-common — that are changing our economic markets … and lives. Visit the world’s key pioneers that persist to success, despite arrows in their backs at http://www.disruptioninterruption.com.

About Karla Jo Helms:

Karla Jo Helms is the Chief Evangelist and Anti-PR™ Strategist for JOTO PR Disruptors™.

Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill back into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.

About DataJoint:

Dimitri Yatsenko is the Chief Executive Office at DataJoint, which is the leading data analysis platform and toolkit for neurophysiology researchers. They develop data science frameworks, platforms, and services for collaborative research, focusing on neuroscience and AI.

With a Ph.D. in Neuroscience (Baylor College of Medicine) and M.S. in Computational Engineering and Science (University of Utah), Dimitri holds an extensive record of projects in academia and industry in areas of signal analysis and image processing, machine learning, medical imaging, data science, and neurophysiology. While engaged in neuroscience research at Baylor College of Medicine, Dimitri started the DataJoint framework as an open source framework — https://datajoint.org. Researchers turned to the project to organize a computational data pipeline spanning multiple labs. After receiving his Ph.D., Dimitri co-founded DataJoint to develop solutions and services for data-driven team science to bridge both social and technical gaps. For more information, visit https://www.datajoint.com

Sources:

1.    Obama White House Archives; “THE BRAIN INITIATIVE. Brain Research through Advancing Innovative Neurotechnologies.” Retrieved 11 August 2022, obamawhitehouse.archives.gov/BRAIN.

2.    University of Zurich. “Every person has a unique brain anatomy.” ScienceDaily. ScienceDaily, 10 July 2018.

BrightStar Care® Expands its Corporate Footprint with Eight Unit BrightStar Owned Acquisition


News Image

BrightStar Care, the leading home care and medical staffing franchise with more than 365 locally owned and operated locations nationwide, announced today that it is acquiring eight BrightStar Care locations from its franchisee David Strassburg. The eight agencies are located throughout Alabama and Florida. They will now operate as BrightStar Owned agencies, making it the largest BrightStar Owned acquisition since the brand launched the program in February 2022.

BrightStar Care created BrightStar Owned to expand the brand’s corporate-owned footprint and utilize these agencies as testing sites for new technologies and processes to advance its franchised locations. BrightStar Owned agencies will also pilot new payer and reimbursement models and accept Medicare Advantage plans and other key national account referrals as part of its business model. This is particularly important because the health care ecosystem is rapidly changing in a direction where Medicare Advantage and other reimbursement models are becoming widely accepted throughout the home care industry. BrightStar Owned intends to use insights and key learnings from its agencies to benefit BrightStar Care franchisees helping to grow their valuation, diversify their skilled care offerings, and scale operations.

Strassburg will lead operations for all eight BrightStar Owned agencies in Alabama and Florida and lead further expansion in these two states, transitioning from owner to Vice President. Over the years, Strassburg, his leadership team, and care staff have built a strong reputation in the communities they served for their quality care. All eight locations specialize in pediatric care and accept Medicaid referrals. Strassburg’s agencies held unique value propositions in the quality of the team and scale of pediatric care that made them prime territories to become BrightStar Owned as the company seeks to add value to franchisees in new revenue models.

“For the last 20 years, BrightStar Care has delivered quality care to seniors and families nationwide. Now through BrightStar Owned we are tactically evolving our model to a format where company-owned locations will provide innovation centers for value-based purchasing arrangements and AI and other technology advancements,” said Shelly Sun, Founder & CEO of BrightStar Care. “We designed BrightStar Owned to align with where the industry is heading and to deliver on our brand mission. BrightStar Owned will expand our reach, make home care more attainable, and increase the client populations we can serve across a diverse payer mix. Ultimately, we desire to contribute to the learning and sharing with our franchisees to lead the industry in the transformation to deliver more care in the home with reimbursements tied to the positive outcomes BrightStar Care delivers.”

“I am honored to partner with BrightStar Owned to continue growing the eight territories that have become part of my enterprise over the past 7 years. I look forward to collaborating with my team and the talented business minds within BrightStar Owned to rapidly grow our network,” said David Strassburg, Vice President of BrightStar Owned AL/FL. “With BrightStar Owned, we have the ability to integrate effectively, learn, document, and take risks without compromising the quality of our care. We will now be able to dream bigger and evolve our operations because we will have far greater resources and expertise to do so.”

With the acquisition of Strassburg’s locations, there are now 13 BrightStar Owned locations operating throughout the country. BrightStar Care franchisees who desire to convert their agencies into BrightStar Owned locations have the option to sell to corporate at above market valuation and stay on as part of the leadership team. It’s an attractive offer for franchisees inching towards retirement and those seeking to scale operations. For more information on BrightStar Care, please visit http://www.brightstarcare.com.

About BrightStar Care:

Founded in 2002, BrightStar Care is a national home care agency with more than 365 franchised locations nationwide that provide medical and non-medical in-home care services to clients in their homes and supplemental care staff to businesses. BrightStar Care franchise agencies across the country employ over 15,000 caregivers and 5,700 registered nurses who oversee the care and safety of each individual client. BrightStar Care offers custom medical staffing solutions to corporate entities and holds national accounts with government agencies across distinct patient populations providing healthcare staff anywhere care is needed. Female founded and led by CEO Shelly Sun, BrightStar Care is committed to providing a higher standard of care through its clinical nurse-led care model. As a member of Moving Health Home, BrightStar Care also actively advocates to change federal and state policies that prevent the home from being an accredited clinical care site. More than 95% of BrightStar Care agencies are Joint Commission accredited – the gold standard within the health care industry. BrightStar Care has also been the only national home care franchise to consecutively receive The Joint Commission’s Enterprise Champion for Quality award for the past decade.

Share article on social media or email:

Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO


Nob Hill Therapeutics

“I’m thrilled to join Nob Hill. Nob Hill is poised to deliver both meaningful therapies to patients and value to its investors. The Nob Hill team has done tremendous work to date, and I look forward to working with them.” added, Noel Greenberger

Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the drug powder formulation and the delivery device (DryNeb) as well as other pre-IND studies.

In addition, NHT has appointed a new Chief Executive Officer. Noel Greenberger will join the company as CEO effective September 1, 2022.

Paul J Atkins, PhD, Executive Chairman NHT, said “This is an exciting time for Nob Hill. Over the past year we have established a strong foundation for the company and continued to develop our platform delivery device (DryNeb). The SBIR grant award further validates the potential benefit of this delivery technology to develop therapies to treat severe lung infections.”

“This grant is built on our successful phase I grant work conducted a year ago, which delivered encouraging animal efficacy study results. The timing is perfect as we are making significant progress on the device which is now in laboratory testing.” Yun Li PhD, Interim CEO, NHT stated.

Noel Greenberger added, “I’m thrilled to join Nob Hill. Nob Hill is poised to deliver both meaningful therapies to patients and value to its investors. The Nob Hill team has done tremendous work to date, and I look forward to working with them and building on the momentum gained during the last several months.”

There are over 250 million people who suffer from lower respiratory tract infections (LTRI) every year and it is the 5th leading cause of death globally. The COVID-19 pandemic has highlighted the urgency for effective respiratory therapies. Inhaled anti-infectives dramatically improve the targeting of therapies to the site of respiratory infections while minimizing systemic exposure and associated toxicity. Currently, there is a paucity of effective treatments to address this unmet medical need.

NHT has a patent-protected inhalation device technology (DryNeb) capable of delivering high therapeutic doses directly to the infected area in the lung. It is suitable for patients of all ages and inhalation capabilities. These factors are critical to ensure treatment efficacy when patients have limited inhalation and coordination capability as in the case with conventional dry powder inhalers.

NHT has assembled a knowledgeable management team and strategic advisors with decades of experience developing therapies for lung diseases. We are delighted that Noel Greenberger (currently a member of our advisory board) will be transitioning to an Executive management role and will provide his wealth of commercial experience as we move the company forward.

About Nob Hill Therapeutics:

Nob Hills Therapeutics patented DryNeb Dry Powder Nebulizer is proven to deliver treatment drugs to the lower respiratory tract with much higher efficiency than the current state-of-the-art dry powder inhalers. Its technology has several key advantages compared to standard dry powder inhalers in generating highly efficient drug aerosols and delivering them effectively to the lower respiratory tract independent of patients’ lung capacity. To learn more, please visit nobhilltherapeutics.com

About VIC Technology Venture Development, LLC

VIC Technology Venture Development creates innovative new companies with world-changing science- and engineering-based technologies. VIC carefully selects and licenses technologies from universities and research institutions worldwide, then partners technology entrepreneurs with VIC’s business and technology experts and allocates seed capital through the national VIC Investor Network. In addition, VIC provides its portfolio companies with senior management expertise, extensive knowledge of technology startups, and proven processes to execute business strategies, including legal, financial, operations, marketing, capital acquisition, and technology management. For more information, please visit victech.com.

Share article on social media or email:

What to Eat, What Not to Eat, and When! Dr. John Jaquish Reveals How to Amplify Your Fat Loss


WSJ Bestselling book, Weightlifting is a Waste of Time – So is Cardio

“Now, using intermittent fasting, there is an additional step to amplify fat loss in a shorter period of time. That additional step is dry fasting with no food or water from sunup to sundown. Anyone can apply this system and will find it a multiplier for losing fat,” Dr. John Jaquish, PhD

When scientist, inventor, and author Dr. John Jaquish started his research into muscle building and fat loss, one of his study objectives was to collect the many different fat loss strategies and analyze them for workability. His research revealed the most effective way to achieve fat loss and amplify one’s ability to lose fat in a shorter period of time is by practicing dry fasting with meal timing and restricted liquid intake. Dr. Jaquish presents his findings with supporting science in his controversial Wall Street Journal bestselling book Weightlifting is a Waste of Time, So is Cardio.

“Of the different fat loss strategies I studied, I found some of them worked very well, some worked well for only a short period of time, and some of them, like caloric restriction, didn’t really work well at all. For 75 years the fitness industry has been saying eat less and move more and Western society is fatter and sicker than ever before,” says Dr. Jaquish.

“And there are still many people who think a calorie is a calorie. However, if you have a calorie of fructose or you have a calorie of protein, each affects the body in a completely different way. A calorie of fructose is borderline poison while a calorie of protein is absolutely needed by the body, especially if it’s essential amino acids,” says Dr. Jaquish.

After concluding that dry fasting is the most effective way to lose fat, in his book Dr. Jaquish details what to eat, what not to eat, and when to eat — which includes the length of time between eating.

“Now, using intermittent fasting, there is an additional step to amplify fat loss in a shorter period of time, which no doubt will make some people very happy. That additional step is dry fasting with no food or water from sunup to sundown. Almost two billion people around the world do this safely for religious reasons. Anyone can apply this system and will find it a multiplier for losing fat,” says Dr. Jaquish.

Briefly, the dry fasting system calls for getting up before the sun rises, having your morning drink and nutrition, not eating from sunup to sundown, and then hydrating and eating a meal after the sun goes down.

Dr. Jaquish reports that something very special happens during the dehydration period. “The body doesn’t want to be dehydrated, so it looks for what non-functioning cells it can pull moisture from that aren’t going to hurt the functioning of the body. The only non-functional cells in the body are fat cells. Every other cell in the body has a function that it needs to perform and needs water to do this, so they can’t give up water.

Pulling the water out of the fat cells causes them to burst and be absorbed by the body, so those cells aren’t there any longer to grow large storing fat again.”

For more information about Dr. Jaquish and to order the book Weightlifting is a Waste of Time – So is Cardio, visit doctorj.com

About John Jaquish, PhD

Scientist, inventor, and author John Jaquish, PhD. has spent years researching and developing improved approaches to health. He speaks at scientific conferences all over the world and is a research professor at Rushmore University. He is the Inventor of the bone density-building medical technology OsteoStrong and the creator of the variable resistance X3 exercise system for accelerated muscle development. Dr. Jaquish’s methods are used in training the world’s most elite athletes, including the Miami Heat, various NFL and NBA players, MMA champions, and members of the US Olympic team. His book, Weightlifting is a Waste of Time – So is Cardio, explains his non-conventional approach to human physiology and is a WSJ Bestseller.

Share article on social media or email:

Kopman Periodontics & Dental Implant Solutions Offering No-Scalpel, No-Suture Laser Treatments in Melville, NY


Kopman Periodontics & Dental Implant Solutions

Kopman Periodontics & Dental Implant Solutions

I encourage anyone who suffers from chronic gum disease or anyone who develops an infection near a dental implant to consider laser treatment. It truly is the most innovative periodontal treatment available.

Kopman Periodontics & Dental Implant Solutions, which provides prosthodontic and periodontal treatments, now offers a variety of laser treatments for patients suffering from periodontal disease, and those who have experienced complications from dental implants.

According to Dr. Jeffrey Kopman, Founder of Kopman Periodontics & Dental Implant Solutions, “Lasers have revolutionized how we treat gum disease. Lasers provide incredible precision which allows for specific targeting of diseased gum tissue only, without harming healthy adjacent tissue. At the same time, using the Laser Assisted New Attachment Procedure™ (LANAP), we can capitalize on the body’s amazing ability to heal itself, by stimulating healthy gum tissues, so that they reattach to the bone. The regrowth of healthy tissue reduces a patient’s likelihood of recurring gum disease.”

Dr. Kopman, who previously taught as a clinical instructor at the Harvard School of Dental Medicine, says that laser technology is helping patients who have experienced complications from dental implants. “Systemic diseases, medications, and aging can all contribute to the development of an infection beneath the gum line,” said Dr. Kopman.

Although dental implants are far superior to dentures and bridges for replacing missing teeth, an infection beneath the gum line near the implant can have serious consequences. “When an infection develops beneath the gum line near an implant, it is crucial to treat the infection as quickly and safely as possible. This is to ensure that the infection doesn’t cause loss of the jawbone that is supporting the implant,” he explained.

To treat an infection near a dental implant, Dr. Kopman uses Laser Assisted Peri-Implantitis Protocol (LAPIP), eliminating the need for an incision, or sutures. “LAPIP, like LANAP, offers precision targeting of infected tissue while stimulating healthy tissue regeneration around the implant,” he explained.

The use of laser therapies for periodontal treatments offers myriad benefits when compared to traditional surgical techniques that require incisions and stitches. Patients can expect a faster recovery, less loss of healthy gum tissue, less discomfort, less bleeding, and healthy tissue regeneration.

“I encourage anyone who suffers from chronic gum disease or anyone who develops an infection near a dental implant to consider laser treatment. It truly is the most innovative periodontal treatment available,” Dr. Kopman said.

Learn more about Kopman Periodontics & Dental Implant Solutions by visiting the practice’s new website: https://www.liperioimplants.com. To schedule a consultation with Dr. Jeffrey Kopman, call 631-351-3444 or request an appointment online.

About Kopman Periodontics & Dental Implant Solutions

Kopman Periodontics & Dental Implant solutions has been a staple in their community since opening in 1971. They specialize in conservative and surgical treatment of gum disease, including cosmetic procedures to aesthetically enhance smiles, as well as dental implants that can replace single or multiple missing teeth. The state-of-the-art office, run by Dr. Jeffrey Kopman, focuses on patient comfort and care. Jeffrey Kopman D.D.S., M.M.SC. earned his Doctor of Dental Surgery from the State University of New York, Buffalo School of Dental Medicine before earning his Certificate of Advanced Graduate Study in Periodontology and a Master of Medical Sciences in Oral Biology from the Harvard School of Dental Medicine. He is currently Clinical Director at the New York Institute of Advanced Dental Studies and Past-President of the Long Island Academy of Periodontology.

Kopman Periodontics & Dental Implant Solutions is located at 999 Walt Whitman Road Suite 303, Melville, NY 11747. Call 631-351-3444 or visit https://www.liperioimplants.com to learn more.

Share article on social media or email:

InstantGMP Inc. celebrates four years with Cartesian Therapeutics


InstantGMP™ celebrates four years of proudly supporting Cartesian Therapeutics’ groundbreaking work in the field of RNA cell therapy

InstantGMP PRO allows us to move from preclinical development to clinical trials quickly,” Kalayoglu stated. “Right now we have three assets in clinical development for three different disease categories. Accomplishing these goals quickly was possible thanks to this all-in-one manufacturing system.

InstantGMP™ celebrates four years of proudly supporting Cartesian Therapeutics’ groundbreaking work in the field of RNA cell therapy via our -all-in-one manufacturing and quality system, InstantGMP PRO.

Based in Gaithersburg, MD, Cartesian Therapeutics is a pioneer in RNA cell therapy. A new category in disease therapeutics, RNA cell therapy combines the RNA from RNA therapeutics with the immune cell from DNA-based cell therapy. This combination allows cells to both produce and deliver RNA therapeutics to the source of the disease in a safer and more precise method.

As a fully integrated company, Cartesian Therapeutics performs all of their discovery, manufacturing and quality management in-house. To help them make this possible, Cartesian Therapeutics searched for a Good Manufacturing Practices (GMP) software that could help them improve their processes, increase productivity, and ensure quality and accuracy at every phase.

They chose the industry’s only all-in-one GMP software: InstantGMP PRO.

“Since we do everything in-house at Cartesian Therapeutics, we wanted to invest in a GMP software that did everything in one system,” said Murat Kalayoglu, MD, PhD, President & Chief Executive Officer of Cartesian Therapeutics. “When we began to research software, we discovered that most products only supported one aspect of GMP manufacturing. There were others that supported multiple needs, but they would still require us to purchase additional platforms to essentially fill in the gaps. When we found InstantGMP PRO, it met all of our needs.”

“Having this all-in-one system in place allows us to move from preclinical development to clinical trials quickly,” Kalayoglu continued. “Right now, we have three assets in clinical development for three different disease categories. Accomplishing these goals so quickly was possible thanks to InstantGMP PRO software.”

As the industry’s only all-in-one GMP software solution, InstantGMP PRO provides Cartesian Therapeutics with the following features:


  • Make To Order Batch Records: Simplifies the development and approval processes for Clinical Trials Material manufacturing.
  • Quality Management System (QMS): Allows users to set quality assurance activities, easily document deviations, perform investigations, and better manage raw materials and outgoing finished products.
  • Inventory Management: Permits users to trace, monitor and record every step of the inventory process.
  • Document Management System (DMS): Enables users to store, organize and secure access to all production files.
  • Sandbox: Provides customers with a completely blank copy of the software so they can test, train, develop and experiment in a safe environment without negatively impacting the information in the official database.


As with all of its GMP software solutions, InstantGMP PRO is frequently updated with new features and benefits, and is validated out of the box. These system updates allow customers like Cartesian Therapeutics to improve their processes so they can remain at the forefront of their industry.

For four years, Cartesian Therapeutics has benefited from the enhanced productivity and quality control provided by InstantGMP PRO software. In turn, InstantGMP has enjoyed supporting this pioneering company and their breakthroughs in RNA cell therapeutics for autoimmune, oncologic, and respiratory disorders.

We look forward to continuing our relationship with Cartesian Therapeutics as they continue to revolutionize the RNA cell therapy industry!

To learn more about InstantGMP PRO all-in-one manufacturing and quality software, contact us to schedule a demonstration.

About InstantGMP™, Inc.

Founded by pharmaceutical industry veteran Dr. Richard Soltero, InstantGMP, Inc., offers affordable all-in-one manufacturing and quality software. The company develops cloud-based electronic batch record software and standard operating procedures specific to industries that are required to follow FDA manufacturing regulations and Good Manufacturing Practices (“GMP”).

As a manufacturing software company, InstantGMP™ pioneered accessible, easy-to-use electronic batch record software for products manufactured using GMPs. The Company’s updated software simplifies the documentation and approval procedures for quality processes that keep all quality documentation organized in an electronic format while providing for quality checks and workflow processes to make compliance with FDA requirements easy.

Share article on social media or email: